Vertex Pharmaceuticals Inc / Ma (VRTX) cash: $5.1B
Vertex Pharmaceuticals Inc / Ma held $5.1B in cash and cash equivalents on Dec 31, 2025, up 11.3% from $4.6B a year earlier.
From Vertex Pharmaceuticals Inc / Ma's filings with the SEC · Read the filing · VRTX stock page
Vertex Pharmaceuticals Inc / Ma cash by year
#124 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $5.1B | +11% |
| Dec 31, 2024 | $4.6B | -56% |
| Dec 31, 2023 | $10.4B | -1% |
| Dec 31, 2022 | $10.5B | +55% |
| Dec 31, 2021 | $6.8B | – |
Cash of similar companies
Companies in the same industry as Vertex Pharmaceuticals Inc / Ma, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| Abbott Laboratories | $8.5B | Dec 31, 2025 |
| Eli Lilly | $7.3B | Dec 31, 2025 |
| AbbVie | $5.2B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $5.1B | Dec 31, 2025 |
| BeOne Medicines | $4.5B | Dec 31, 2025 |
| TEVA Pharmaceutical Industries | $3.6B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $3.1B | Dec 31, 2025 |
Questions and answers
What is Vertex Pharmaceuticals Inc / Ma's cash?
Vertex Pharmaceuticals Inc / Ma held $5.1B in cash and cash equivalents on Dec 31, 2025, up 11.3% from $4.6B a year earlier.
Numbers as reported in Vertex Pharmaceuticals Inc / Ma's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology